Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer

1Zadnik V, Primic Žakelj M. SLORA: Slovenija in rak. Epidemiologija in register raka. Ljubljana: Epidemiologija in register raka. Onkološki inštitut Ljubljana. [cited 2019 April 15]. Available at: http://www.slora.si Zadnik V Primic Žakelj M SLORA: Slovenija in rak. Epidemiologija in register raka Ljubljana Epidemiologija in register raka. Onkološki inštitut Ljubljana [cited 2019 April 15]. Available at http://www.slora.siSearch in Google Scholar

2Curigliano G, Burstein HJ, Winer E, Gnant M, Dubsky P, Loibl S, et al. Deescalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28: 1700-12. doi: 10.1093/ annonc/mdx308 Curigliano G Burstein HJ Winer E Gnant M Dubsky P Loibl S et al Deescalating and escalating treatments for early-stage breast cancer: the St Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Ann Oncol 2017; 28 1700 12 10.1093/ annonc/mdx308Open DOISearch in Google Scholar

3Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379: 432-44. doi: 10.1016/S0140-6736(11)61625-5 Peto R Davies C Godwin J Gray R Pan HC Clarke M et al Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 2012 379 432 44 10.1016/S0140-6736(11)61625-5327372322152853Open DOISearch in Google Scholar

4Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717. doi: 10.1016/S0140-6736(05)66544-0 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 2005 365 1687 717 10.1016/S0140-6736(05)66544-015894097Open DOISearch in Google Scholar

5Mamounas EP, Russell CA, Lau A, Turner MP, Albain KS. Clinical relevance of the 21-gene Recurrence Score((R)) assay in treatment decisions for patients with node-positive breast cancer in the genomic era. NPJ Breast Cancer 2018; 4: 27. doi: 10.1038/s41523-018-0082-6 Mamounas EP Russell CA Lau A Turner MP Albain KS Clinical relevance of the 21-gene Recurrence Score((R)) assay in treatment decisions for patients with node-positive breast cancer in the genomic era NPJ Breast Cancer 2018 4 27 10.1038/s41523-018-0082-6610229630155517Open DOISearch in Google Scholar

6Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 2017; 75: 284-98. doi: 10.1016/j.ejca.2017.01.017 Duffy MJ Harbeck N Nap M Molina R Nicolini A Senkus E et al Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM) Eur J Cancer 2017 75 284 98 10.1016/j.ejca.2017.01.01728259011Open DOISearch in Google Scholar

7Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, et al. Use of bio-markers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 2017; 35: 2838-47. doi: 10.1200/JCO.2017.74.0472 Krop I Ismaila N Andre F Bast RC Barlow W Collyar DE et al Use of bio-markers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update J Clin Oncol 2017 35 2838 47 10.1200/JCO.2017.74.0472584618828692382Open DOISearch in Google Scholar

8Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 Suppl 5: v8-30. doi: 10.1093/ annonc/mdv298 Senkus E Kyriakides S Ohno S Penault-Llorca F Poortmans P Rutgers E et al Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 2015 26 Suppl 5 v8 30 10.1093/ annonc/mdv298Open DOISearch in Google Scholar

9National Comprehensive Cancer Network. NCCN Guidelines Version 1.2019 Breast Cancer.[cited 2019 June 6] Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf National Comprehensive Cancer Network. NCCN Guidelines Version 1.2019 Breast Cancer [cited 2019 June 6] Available at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdfSearch in Google Scholar

10Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65. doi: 10.1016/S1470-2045(09)70314-6 Albain KS Barlow WE Shak S Hortobagyi GN Livingston RB Yeh IT et al Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 2010 11 55 65 10.1016/S1470-2045(09)70314-6305823920005174Open DOISearch in Google Scholar

11Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26. doi: 10.1056/NEJMoa041588 Paik S Shak S Tang G Kim C Baker J Cronin M et al A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 2004 351 2817 26 10.1056/NEJMoa04158815591335Open DOISearch in Google Scholar

12Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-34. doi: 10.1200/ JCO.2005.04.7985 Paik S Tang G Shak S Kim C Baker J Kim W et al Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 2006 24 3726 34 10.1200/ JCO.2005.04.7985Open DOISearch in Google Scholar

13Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018; 379: 111-21. doi: 10.1056/NEJMoa1804710 Sparano JA Gray RJ Makower DF Pritchard KI Albain KS Hayes DF et al Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer N Engl J Med 2018 379 111 21 10.1056/NEJMoa1804710617265829860917Open DOISearch in Google Scholar

14Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010; 28: 1829-34. doi: 10.1200/JCO.2009.24.4798 Dowsett M Cuzick J Wale C Forbes J Mallon EA Salter J et al Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study J Clin Oncol 2010 28 1829 34 10.1200/JCO.2009.24.479820212256Open DOISearch in Google Scholar

15Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-52. doi: 10.1093/jnci/djp335 Simon RM Paik S Hayes DF Use of archived specimens in evaluation of prognostic and predictive biomarkers J Natl Cancer Inst 2009 101 1446 52 10.1093/jnci/djp335278224619815849Open DOISearch in Google Scholar

16Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, et al. West German Study Group Phase III PlanB Trial: First prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 2016; 34: 2341-9. doi: 10.1200/JCO.2015.63.5383 Gluz O Nitz UA Christgen M Kates RE Shak S Clemens M et al West German Study Group Phase III PlanB Trial: First prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment J Clin Oncol 2016 34 2341 9 10.1200/JCO.2015.63.538326926676Open DOISearch in Google Scholar

17Roberts MC, Miller DP, Shak S, Petkov VI. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database. Breast Cancer Res Treat 2017; 163: 303-10. doi: 10.1007/s10549-017-4162-3 Roberts MC Miller DP Shak S Petkov VI Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database Breast Cancer Res Treat 2017 163 303 10 10.1007/s10549-017-4162-328243896Open DOISearch in Google Scholar

18Stemmer SM, Steiner M, Rizel S, Geffen DB, Nisenbaum B, Peretz T, et al. Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry. NPJ Breast Cancer 2017; 3: 32. doi: 10.1038/s41523-017-0033-7 Stemmer SM Steiner M Rizel S Geffen DB Nisenbaum B Peretz T et al Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry NPJ Breast Cancer 2017 3 32 10.1038/s41523-017-0033-7559131428900632Open DOISearch in Google Scholar

19ClinicalTrials.gov Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer. [cited 2019 July 11] Available at: https://clinicaltrials.gov/ct2/show/NCT01272037 ClinicalTrials.gov Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer [cited 2019 July 11] Available at https://clinicaltrials.gov/ct2/show/NCT01272037Search in Google Scholar

20van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6. doi: 10.1038/415530a van ‘t Veer LJ Dai H van de Vijver MJ He YD Hart AA Mao M et al Gene expression profiling predicts clinical outcome of breast cancer Nature 2002 415 530 6 10.1038/415530a11823860Open DOISearch in Google Scholar

21Tian S, Roepman P, Van’t Veer LJ, Bernards R, de Snoo F, Glas AM. Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomark Insights 2010; 5: 129-38. doi: 10.4137/BMI. S6184 Tian S Roepman P Van’t Veer LJ Bernards R de Snoo F Glas AM Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer Biomark Insights 2010 5 129 38 10.4137/BMI. S6184Open DOISearch in Google Scholar

22van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009. doi: 10.1056/NEJMoa021967 van de Vijver MJ He YD van’t Veer LJ Dai H Hart AA Voskuil DW et al A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 2002 347 1999 2009 10.1056/NEJMoa02196712490681Open DOISearch in Google Scholar

23Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-92. doi: 10.1093/ jnci/djj329 Buyse M Loi S van’t Veer L Viale G Delorenzi M Glas AM et al Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 2006 98 1183 92 10.1093/ jnci/djj329Open DOISearch in Google Scholar

24Sapino A, Roepman P, Linn SC, Snel MH, Delahaye LJ, van den Akker J, et al. MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. J Mol Diagn 2014; 16: 190-7. doi: 10.1016/j.jmoldx.2013.10.008 Sapino A Roepman P Linn SC Snel MH Delahaye LJ van den Akker J et al MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue J Mol Diagn 2014 16 190 7 10.1016/j.jmoldx.2013.10.00824378251Open DOISearch in Google Scholar

25Drukker CA, Bueno-de-Mesquita JM, Retel VP, van Harten WH, van Tinteren H, Wesseling J, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 2013; 133: 929-36. doi: 10.1002/ijc.28082 Drukker CA Bueno-de-Mesquita JM Retel VP van Harten WH van Tinteren H Wesseling J et al A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study Int J Cancer 2013 133 929 36 10.1002/ijc.28082373462523371464Open DOISearch in Google Scholar

26Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23: 2716-25. doi: 10.1200/JCO.2005.06.178 Olivotto IA Bajdik CD Ravdin PM Speers CH Coldman AJ Norris BD et al Population-based validation of the prognostic model ADJUVANT! for early breast cancer J Clin Oncol 2005 23 2716 25 10.1200/JCO.2005.06.17815837986Open DOISearch in Google Scholar

27Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 2010; 21: 717-22. doi: 10.1093/annonc/mdp388 Mook S Schmidt MK Weigelt B Kreike B Eekhout I van de Vijver MJ et al The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age Ann Oncol 2010 21 717 22 10.1093/annonc/mdp38819825882Open DOISearch in Google Scholar

28Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006; 3: 540-51. doi: 10.1038/ ncponc0591 Bogaerts J Cardoso F Buyse M Braga S Loi S Harrison JA et al Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial Nat Clin Pract Oncol 2006 3 540 51 10.1038/ ncponc0591Open DOISearch in Google Scholar

29Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008; 26: 729-35. doi: 10.1200/JCO.2007.14.3222 Cardoso F Van’t Veer L Rutgers E Loi S Mook S Piccart-Gebhart MJ Clinical application of the 70-gene profile: the MINDACT trial J Clin Oncol 2008 26 729 35 10.1200/JCO.2007.14.322218258980Open DOISearch in Google Scholar

30Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016; 375: 717-29. doi: 10.1056/NEJMoa1602253 Cardoso F van’t Veer LJ Bogaerts J Slaets L Viale G Delaloge S et al 70-Gene signature as an aid to treatment decisions in early-stage breast cancer N Engl J Med 2016 375 717 29 10.1056/NEJMoa160225327557300Open DOISearch in Google Scholar

31Esserman LJ, Yau C, Thompson CK, van ‘t Veer LJ, Borowsky AD, Hoadley KA, et al. Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. JAMA Oncol 2017; 3: 1503-10. doi: 10.1001/jamaoncol.2017.1261 Esserman LJ Yau C Thompson CK van ‘t Veer LJ Borowsky AD Hoadley KA et al Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades JAMA Oncol 2017 3 1503 10 10.1001/jamaoncol.2017.1261571019728662222Open DOISearch in Google Scholar

32Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer 2013; 109: 2959-64. doi: 10.1038/bjc.2013.671 Dubsky P Brase JC Jakesz R Rudas M Singer CF Greil R et al The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients Br J Cancer 2013 109 2959 64 10.1038/bjc.2013.671385994924157828Open DOISearch in Google Scholar

33Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17: 6012-20. doi: 10.1158/1078-0432.CCR-11-0926 Filipits M Rudas M Jakesz R Dubsky P Fitzal F Singer CF et al A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors Clin Cancer Res 2011 17 6012 20 10.1158/1078-0432.CCR-11-092621807638Open DOISearch in Google Scholar

34Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-7. doi: 10.1200/JCO.2008.18.1370 Parker JS Mullins M Cheang MC Leung S Voduc D Vickery T et al Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 2009 27 1160 7 10.1200/JCO.2008.18.1370266782019204204Open DOISearch in Google Scholar

35Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2014; 25: 339-45. doi: 10.1093/annonc/mdt494 Gnant M Filipits M Greil R Stoeger H Rudas M Bago-Horvath Z et al Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone Ann Oncol 2014 25 339 45 10.1093/annonc/mdt49424347518Open DOISearch in Google Scholar

36Jerevall PL, Ma XJ, Li H, Salunga R, Kesty NC, Erlander MG, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 2011; 104: 1762-9. doi: 10.1038/bjc.2011.145 Jerevall PL Ma XJ Li H Salunga R Kesty NC Erlander MG et al Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial Br J Cancer 2011 104 1762 9 10.1038/bjc.2011.145311115921559019Open DOISearch in Google Scholar

37Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 2013; 105: 1036-42. doi: 10.1093/jnci/djt146 Sgroi DC Carney E Zarrella E Steffel L Binns SN Finkelstein DM et al Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker J Natl Cancer Inst 2013 105 1036 42 10.1093/jnci/djt146388813823812955Open DOISearch in Google Scholar

38Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013; 31: 2783-90. doi: 10.1200/JCO.2012.46.1558 Dowsett M Sestak I Lopez-Knowles E Sidhu K Dunbier AK Cowens JW et al Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy J Clin Oncol 2013 31 2783 90 10.1200/JCO.2012.46.155823816962Open DOISearch in Google Scholar

39Harbeck N, Thomssen C. A new look at node-negative breast cancer. Oncologist 2011; 16 Suppl 1: 51-60. doi: 10.1634/theoncologist.2011-S1-51 Harbeck N Thomssen C A new look at node-negative breast cancer Oncologist 2011 16 Suppl 1 51 60 10.1634/theoncologist.2011-S1-5121278441Open DOISearch in Google Scholar

40Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009; 116: 295-302. doi: 10.1007/s10549-008-0130-2 Mook S Schmidt MK Viale G Pruneri G Eekhout I Floore A et al The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study Breast Cancer Res Treat 2009 116 295 302 10.1007/s10549-008-0130-218661261Open DOISearch in Google Scholar

41Chang MC, Souter LH, Kamel-Reid S, Rutherford M, Bedard P, Trudeau M, et al. Clinical utility of multigene profiling assays in early-stage breast cancer. Curr Oncol 2017; 24: e403-e22. doi: 10.3747/co.24.3595 Chang MC Souter LH Kamel-Reid S Rutherford M Bedard P Trudeau M et al Clinical utility of multigene profiling assays in early-stage breast cancer Curr Oncol 2017 24 e403 e22 10.3747/co.24.3595565916529089811Open DOISearch in Google Scholar

42Clark GM. Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib. Mol Oncol 2008; 1: 406-12. doi: 10.1016/j.molonc.2007.12.001 Clark GM Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib Mol Oncol 2008 1 406 12 10.1016/j.molonc.2007.12.001554383219383314Open DOISearch in Google Scholar

43Ballman KV. Biomarker: Predictive or Prognostic? J Clin Oncol 2015; 33: 3968-71. doi: 10.1200/JCO.2015.63.3651 Ballman KV Biomarker: Predictive or Prognostic? J Clin Oncol 2015 33 3968 71 10.1200/JCO.2015.63.365126392104Open DOISearch in Google Scholar

44Bhutiani N, Egger ME, Ajkay N, Scoggins CR, Martin RC, 2nd, McMasters KM. Multigene signature panels and breast cancer therapy: patterns of use and impact on clinical decision making. J Am Coll Surg 2018; 226: 406-12 e1. doi: 10.1016/j.jamcollsurg.2017.12.043 Bhutiani N Egger ME Ajkay N Scoggins CR Martin RC 2nd McMasters KM Multigene signature panels and breast cancer therapy: patterns of use and impact on clinical decision making J Am Coll Surg 2018 226 406 12 e1 10.1016/j.jamcollsurg.2017.12.04329366844Open DOISearch in Google Scholar

45Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer 2016; 2: 16017. doi: 10.1038/npjbcancer.2016.17 Petkov VI Miller DP Howlader N Gliner N Howe W Schussler N et al Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study NPJ Breast Cancer 2016 2 16017 10.1038/npjbcancer.2016.17551532928721379Open DOISearch in Google Scholar

46Su KW, Hall J, Soulos PR, Abu-Khalaf MM, Evans SB, Mougalian SS, et al. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011. J Geriatr Oncol 2016; 7: 15-23. doi: 10.1016/j.jgo.2015.11.002 Su KW Hall J Soulos PR Abu-Khalaf MM Evans SB Mougalian SS et al Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011 J Geriatr Oncol 2016 7 15 23 10.1016/j.jgo.2015.11.00226704661Open DOISearch in Google Scholar

47Potosky AL, O’Neill SC, Isaacs C, Tsai HT, Chao C, Liu C, et al. Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years. Cancer 2015; 121: 4062-70. doi: 10.1002/cncr.29621 Potosky AL O’Neill SC Isaacs C Tsai HT Chao C Liu C et al Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years Cancer 2015 121 4062 70 10.1002/cncr.29621463504226291519Open DOISearch in Google Scholar

48Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 2012; 30: 2218-26. doi: 10.1200/JCO.2011.38.5740 Hassett MJ Silver SM Hughes ME Blayney DW Edge SB Herman JG et al Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer J Clin Oncol 2012 30 2218 26 10.1200/JCO.2011.38.5740339771822585699Open DOISearch in Google Scholar

49Blok EJ, Bastiaannet E, van den Hout WB, Liefers GJ, Smit V, Kroep JR, et al. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. Cancer Treat Rev 2018; 62: 74-90. doi: 10.1016/j.ctrv.2017.10.012 Blok EJ Bastiaannet E van den Hout WB Liefers GJ Smit V Kroep JR et al Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe Cancer Treat Rev 2018 62 74 90 10.1016/j.ctrv.2017.10.01229175678Open DOISearch in Google Scholar

50Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 2018; 4: 545-53. doi: 10.1001/jamaoncol.2017.5524 Sestak I Buus R Cuzick J Dubsky P Kronenwett R Denkert C et al Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial JAMA Oncol 2018 4 545 53 10.1001/jamaoncol.2017.5524588522229450494Open DOISearch in Google Scholar

51Bartlett JM, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, et al. Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. J Natl Cancer Inst 2016; 108: pii: djw050. doi: 10. 1093/jnci/djw050 Bartlett JM Bayani J Marshall A Dunn JA Campbell A Cunningham C et al Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others J Natl Cancer Inst 2016 108 pii: djw050 10. 1093/jnci/djw050Open DOISearch in Google Scholar